Selected
Type of publications
Regions
Countries
Diseases
Publication date
Target population
Available to download in languages
722 results found
2024 ∙ ATAGI
ATAGI statement on Nirsevimab for the prevention of severe disease due to respiratory syncytial virus (RSV) in infants
  • Children
  • Recommendation
  • Australia
  • RSV (Respiratory syncytial virus)
Download:
2023 ∙ Mohammed, H. Pham-Tran, D. D. Yeoh, Z. Y. M. Wang, B. McMillan, M. Andraweera, P. H. Marshall, H. S.
A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
  • Vaccine/vaccination
  • Efficacy/effectiveness
  • All age groups
  • Healthcare workers
  • COVID-19
Rating:
Critically low
2023 ∙ Whitehead, H. S. French, C. E. Caldwell, D. M. Letley, L. Mounier-Jack, S.
A systematic review of communication interventions for countering vaccine misinformation
  • Vaccine/vaccination
  • Acceptance
  • All age groups
  • Parents/caregivers
  • COVID-19
Rating:
Not applicable
2023 ∙ Mavundza, E. J. Cooper, S. Wiysonge, C. S.
A Systematic Review of Factors That Influence Parents’ Views and Practices around Routine Childhood Vaccination in Africa: A Qualitative Evidence Synthesis
  • Acceptance
  • Parents/caregivers
Rating:
Not applicable
2023 ∙ Jagne, Isatou von Mollendorf, Claire Wee-Hee, Ashleigh Ortika, Belinda Satzke, Catherine Russell, Fiona M.
A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age
  • Efficacy/effectiveness
  • Newborn
  • Children
  • Pneumococcal disease
Rating:
Low
2023 ∙ Doggen, Kris van Hoek, Albert Jan Luyten, Jeroen
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
  • Economic aspects
  • Newborn
  • Children
  • Adolescents
  • Adults
  • Pneumococcal disease
  • Rotavirus
  • Human papillomavirus (HPV)
  • Meningococcal disease
  • Mumps
  • Measles
  • Rubella
Rating:
Not applicable
2023 ∙ Dadari, I. Belt, R. V. Iyengar, A. Ray, A. Hossain, I. Ali, D. Danielsson, N. Sodha, S. V.
Achieving the IA2030 Coverage and Equity Goals through a Renewed Focus on Urban Immunization
  • Coverage
  • Ethical issues
  • Newborn
  • Children
  • Adolescents
Rating:
Not applicable
2023 ∙ Pichichero, Michael Malley, Richard Kaur, Ravinder Zagursky, Robert Anderson, Porter
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines
  • Efficacy/effectiveness
  • Children
  • Adolescents
  • Pneumococcal disease
Rating:
Critically low
2023 ∙ Watanabe, A. Kani, R. Iwagami, M. Takagi, H. Yasuhara, J. Kuno, T.
Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis
  • Efficacy/effectiveness
  • Safety
  • Vaccine/vaccination
  • Children
  • Adolescents
  • COVID-19
Rating:
Critically low
2023 ∙ Bansal, D. Kamboj, M. Anand, R. Pandiar, D. Narwal, A. Sivakumar, N. Devi, A.
Association of childhood vaccination with pediatric lichen planus: A systematic review
  • Safety
  • Children
  • Adolescents
Rating:
Critically low